NCT02929862 - Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions

Cancer

Interventions

DRUG

LYC-55716

For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.

Trial Locations (20)

10016

Lycera Investigational Site, New York

19111

Lycera Investigational Site, Philadelphia

20007

Lycera Investigational Site, Washington D.C.

22031

Lycera Investigational Site, Fairfax

22908

Lycera Investigational Site, Charlottesville

27710

Lycera Investigational Site, Durham

29605

Lycera Investigational Site, Greenville

30322

Lycera Investigational Site, Atlanta

30912

Lycera Investigational Site, Augusta

34232

Lycera Investigational Site, Sarasota

35805

Lycera Investigational Site, Huntsville

37203

Lycera Investigational Site, Nashville

56303

Lycera Investigational Site, Saint Cloud

60611

Lycera Investigational Site, Chicago

68130

Lycera Investigational Site, Omaha

73104

Lycera Investigational Site, Oklahoma City

75230

Lycera Investigational Site, Dallas

78229

Lycera Investigational Site, San Antonio

95817

Lycera Investigational Site, Sacramento

97213

Lycera Investigational Site, Portland

All Listed Sponsors

lead

Lycera Corp.

INDUSTRY